Parkinsonism & Related Disorders
Volume 14, Issue 6 , Pages 451-456 , August 2008

Sexual dysfunction in Parkinson's disease

  • Giuseppe Meco

      Affiliations

    • Dipartimento di Scienze Neurologiche, University of Rome “La Sapienza”, Viale dell'Universita 30, 00185 Roma, Italy
    • Centro di Ricerca di Medicina Sociale (C.I.M.S.), University of Rome “La Sapienza”, Italy
    • Corresponding Author InformationCorresponding author. Dipartimento di Scienze Neurologiche, University of Rome “La Sapienza”, Viale dell'Universita 30, 00185 Roma, Italy. Tel.: +39 06 4991 4706; fax: +39 06 4991 4840.
    • ,
  • Alfonso Rubino

      Affiliations

    • Dipartimento di Scienze Neurologiche, University of Rome “La Sapienza”, Viale dell'Universita 30, 00185 Roma, Italy
    • ,
  • Natalia Caravona

      Affiliations

    • Dipartimento di Scienze Neurologiche, University of Rome “La Sapienza”, Viale dell'Universita 30, 00185 Roma, Italy
    • Centro di Ricerca di Medicina Sociale (C.I.M.S.), University of Rome “La Sapienza”, Italy
    • ,
  • Marcella Valente

      Affiliations

    • Dipartimento di Scienze Neurologiche, University of Rome “La Sapienza”, Viale dell'Universita 30, 00185 Roma, Italy
    • Centro di Ricerca di Medicina Sociale (C.I.M.S.), University of Rome “La Sapienza”, Italy

Received 8 June 2007 ,Revised 23 October 2007 ,Accepted 24 October 2007.

References 

  1. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord. Dec 2006;21(12):2042–2051
  2. Dominguez JM, Hull EM. Dopamine, the medial preoptic area, and male sexual behaviour. Physiol Behav. 8 Feb 2005;26(6):1699–1703
  3. Matuszewich L, Lorrain DS, Hull EM. Dopamine release in the medial preoptic area of female rats in response to hormonal manipulation and sexual activity. Behav Neurosci. 2000;114:772–782
  4. Hull EM, Dominguez JM. Getting his act together: roles of glutamate, nitric oxide, and dopamine in the medial preoptic area. Brain Res. 18 Dec 2006;1126(1):66–75
  5. Witt DM, Insel TR. Increased Fos expression in oxytocin neurons following masculine sexual behaviour. J Neuroendocrinol. Feb 1994;6(1):13–18
  6. Argilas A, Melis MR. The role of oxytocin and the paraventricular nucleus in the sexual behaviour of male mammals. Physiol Behav. 15 Nov 2004;83(2):309–317
  7. Fibiger HC, Phillips AG. Mesocortico-limbic dopamine-system and reward. Ann N Y Acad Sci. 1988;537:206–215
  8. Everitt BJ. Sexual motivation a neural behavioural analysis of the mechanism underlying appetitive and copulatory response male rats. Neurosci Biobehav Rev. Summer 1990;14(2):217–232
  9. Liu YC, Sachs BD, Salomone JD. Sexual behavior in male rats after radiofrequency or dopamine depleting lesions in nucleus accumbens. Pharmacol Biochem Behav. Jun 1998;60(2):585–592
  10. Succu S, Sanna F, Melis T, Boi A, Argiolas A, Melis MR. Stimulation of dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces penile erection and increases extra-cellular dopamine in the nucleus accumbens: involvement of central oxytocin. Neuropharm. Mar 2007;52(3):1034–1043[Epub 2006 Dec 11]
  11. Kruger TH, Hartmann U, Schedlowski M. Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans. World J Urol. Jun 2005;23(2):130–138[Epub 2005 May 12]
  12. Paredes RG, Agmo A. Has dopamine a physiological role in the control of sexual behavior? A critical review of the evidence. Prog Neurobiol. Jun 2004;73(3):179–226
  13. Ferguson JM. SSRI antidepressant, medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. Feb 2001;3(1):22–27
  14. Basson R. Sexuality and Parkinson's disease. Parkinsonism Relat disord. 1996;2:177–185
  15. Bancroft JH. Sex and aging. N Engl J Med. 23 Aug 2007;357(8):820–822
  16. Basson R, Schultz WW. Sexual sequelae of general medical disorders. Lancet. 3 Feb 2007;369(9559):409–424[Review]
  17. Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006;2(4):447–455
  18. Frohman EM. Sexual dysfunction in neurologic disease. Clin Neuropharmacol. 2002;25:126–132
  19. Koller WC, Vetere-Overfield B, Williamson A, Busenbark K, Nash J, Parrish D. Sexual dysfunction in Parkinson's disease. Clin Neuropharmacol. 8 Oct 1990;13(5):461–463
  20. Brown RG, Jahanshahi M, Quinn N, Marsden CD. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry. Jun 1990;53(6):480–486
  21. Calne SM, Mak E, Hall J, Fortin MJ, King P, McInnes G, et al. Validating a quality-of-life scale in caregivers of patients with Parkinson's disease: Parkinson's impact scale (PIMS). Adv Neurol. 2003;91:115–122
  22. Schulzer M, Mak E, Calne SM. The psychometric properties of the Parkinson's impact scale (PIMS) as a measure of quality of life in Parkinson's disease. Parkinsonism Relat Disord. Jun 2003;9(5):291–294
  23. Lipe H, Longstreth WT, Bird TD, Linde M. Sexual function in married men with Parkinson's disease compared to married men with arthritis. Neurology. Sep 1990;40(9):1347–1349
  24. Singer C, Weiner WJ, Sanchez-Ramos J, Ackerman M. Sexual function in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. Oct 1991;54(10):942
  25. Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson's disease patients and normal control. Parkinsonism Relat disord. 2003;10:67–71
  26. Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci. 2001;92:76–85
  27. Welsh M, Hung L, Waters CH. Sexuality in women with Parkinson's disease. Mov Disord. Nov 1997;12(6):923–927
  28. Brown E, Brown GM, Kofman O, Quarington B. Sexual function and affect in Parkinsonian men treated with l-Dopa. Am J Psychiatry. 1978;135:1552–1557
  29. Wermuth L, Stenager E. Sexual problems in young patients with Parkinson's disease. Acta Neurol Scand. Jun 1995;91(6):453–455
  30. Bronner G, Royter V, Korczyn AD, Giladi N. Sexual dysfunction in Parkinson's disease. J Sex Marital Ther. Mar–Apr 2004;30(2):95–105
  31. Cleeves E, Findley L. Bromocriptine induced impotence in Parkinson's disease. Br Med J. 1987;295:367–368
  32. Yu M, Roane DM, Miner CR, Fleming M, Rogers JD. Dimensions of sexual dysfunction in Parkinson disease. Am J Geriatr Psychiatry. Mar–Apr 2004;12(2):221–226
  33. Moore O, Gurevich T, Korczyn AD, Anca M, Shabtai H, Giladi . Quality of sexual life in Parkinson's disease. Parkinsonism Relat disord. 2002;8:243–246
  34. Dubow JS. Autonomic dysfunction in Parkinson's disease. Dis Mon. May 2007;53(5):265–274[Review]
  35. Kaufmann H, Biaggioni I. Autonomic failure in neurodegenerative disorders. Semin Neurol. Dec 2003;23(4):351–363[Review]
  36. Oertel WH, Wachter T, Quinn NP, Ulm G, Brandstadter D. Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type. Mov Disord. 2003;18:430–432
  37. Jost WH, Eckardt VF. Constipation in idiopathic Parkinson's disease. Scand J Gastroenterol. 2003;7:681–686
  38. Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75:1470–1471
  39. De Lamater JD, Sill M. Sexual desire in later life. J Sex Res. 2005;42:138–149
  40. Yahr MD, Duvoisin RC. Drug therapy of parkinsonism. N Engl J Med. 6 Jul 1972;287(1):20–24
  41. Goodwin FK, Murphy DL, Brodie HK, Bunney WE. Levodopa: alterations in behavior. Clin Pharmacol Ther. Mar–Apr 1971;12(2):383–396
  42. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. Jul 2006;63(7):969–973
  43. Harvey NS. Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry. Dec 1988;153:833–836
  44. O'Sullivan JD. Apomorphine as an alternative to sildenafil in Parkinson's disease. J Neurol Neurosurg Psychiatry. May 2002;72(5):681
  45. Fine J, Lang AE. Dose-induced penile erections in response to ropinirole therapy for Parkinson's disease. Mov Disord. Jul 1999;14(4):701–702
  46. Jimenez-Jimenez FJ, Tallon-Barranco A, Cabrera-Valdivia F, Gasalla T, Orti-Pareja M, Zurdo M. Fluctuating penile erection related with levodopa therapy. Neurology. 1 Jan 1999;52(1):210
  47. Pohanka M, Kanovsky P, Bares M, Pulkrabek J, Rektor I. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. Eur J Neurol. Jul 2004;11(7):483–488
  48. Castelli L, Perozzo P, Genesia ML, Torre E, Pesare M, Cinquepalmi A, et al. Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry. Sep 2004;75(9):1260–1264
  49. Sandyk R. AC pulsed electromagnetic fields-induced sexual arousal and penile erections in Parkinson's disease. Int J Neurosci. Aug 1999;99(1–4):139–149
  50. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord. Mar 2000;15(2):305–308
  51. Raffaele R, Vecchio I, Giammusso B, Morgia G, Brunetto MB, Rampello L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol. Apr 2002;41(4):382–386
  52. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. Apr 2000;68(4):423–428
  53. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?. Lancet Neurol. Oct 2003;2(10):595–604[Review]
  54. Pezzella FR, Colosimo C, Vanacore N, Di Rezze S, Chianese M, Fabbrini G, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord. Jan 2005;20(1):77–81
  55. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology. 22 Nov 2005;65(10):1570–1574
  56. Dekker M, Bonifati V, van Swieten J, Leenders N, Galjaard RJ, Snijders P, et al. Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov Disord. 2003;18:751–757
  57. Ch Berger, Mehrhoff FW, Beier KM, Meinck HM. Sexual delinquency and Parkinson's disease. Nervenarzt. Apr 2003;74(4):370–375
  58. Jimenez-Jimenez FJ, Sayed Y, Garcia-Soldevilla MA, Barcenilla B. Possible zoophilia associated with dopaminergic therapy in Parkinson disease. Ann Pharmacother. Jul–Aug 2002;36(7–8):1178–1179
  59. Cannas A, Solla P, Floris G, Tacconi P, Loi D, Marcia E, et al. Hypersexual behaviour, frotteurism and delusional jealousy in a young parkinsonian patient during dopaminergic therapy with pergolide: a rare case of iatrogenic paraphilia. Prog Neuropsychopharmacol Biol Psychiatry. 30 Dec 2006;30(8):1539–1541
  60. Riley DE. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. Clin Neuropharmacol. Jul–Aug 2002;25(4):234–237
  61. Shapiro MA, Chang YL, Munson SK, Okun MS, Fernandez HH. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord. Sep 2006;12(6):392–395
  62. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord. Sep 2005;11(6):381–386
  63. Roane DM, Yu M, Feinberg TE, Rogers JD. Hypersexuality after pallidal surgery in Parkinson disease. Neuropsychiatry Neuropsychol Behav Neurol. Dec 2002;15(4):274–351
  64. Mendez MF, O'Connor SM, Lim GT. Hypersexuality after right pallidotomy for Parkinson's disease. J Neuropsychiatry Clin Neurosci. Winter 2004;16(1):37–40
  65. Menza MA, Golbe LI, Cody RA, Forman NE. Dopamine-related personality traits in Parkinson's disease. Neurology. 1993;43:505–508
  66. Uitti RJ, Tanner CM, Rajput AH, Klawans HL, Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989;12:375–383
  67. Fernandez HH, Durso R. Clozapine for dopaminergic-induced paraphilias in Parkinson's disease. Mov Disord. May 1998;13(3):597–598
  68. Kafka MP. The monoamine hypothesis for the pathophysiology of paraphilic disorders: an update. Ann N Y Acad Sci. Jun 2003;989:86–94[Discussion 144–53]
  69. Ivanco LS, Bohnen NI. Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. Am J Ther. Sep–Oct 2005;12(5):467–468
  70. Rees PM, Fowler CJ, Maas CP. Sexual function in men and women with neurological disorders. Lancet. 10 Feb 2007;369(9560):512–525
  71. Redoute J, Stoleru S, Pugeat M, Costes N, Lavenne F, Le Bars D, et al. Brain processing of visual sexual stimuli in treated and untreated hypogonadal patients. Psychoneuroendocrinology. Jun 2005;30(5):461–482
  72. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol. 1997;38(Suppl. 2):2–7

PII: S1353-8020(07)00246-5

doi: 10.1016/j.parkreldis.2007.10.008

Parkinsonism & Related Disorders
Volume 14, Issue 6 , Pages 451-456 , August 2008

Article Tools